POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

• M. Dimopoulos,
• K. Weisel,
• P. Moreau,
• L.D.A. Jr,
• D. White,
• J.S. Miguel,
• P. Sonneveld,
• M. Engelhardt,
• M. Jenner,
• A. Corso,
• J. Dürig,
• M. Pavic,
• M. Salomo,
• E. Casal,
• R. Jiang,
• T. Nguyen,
• T. Peluso,
• P. Richardson

Affiliations

M. Dimopoulos

National and Kapodistrian University of Athens, Athens, Greece

K. Weisel

Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P. Moreau

University Hospital Hôtel-Dieu, Nantes, France

L.D.A. Jr

UT Southwestern Medical Center, Dallas, United States

D. White

Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada

J.S. Miguel

Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain

P. Sonneveld

Erasmus MC Cancer Institute, Rotterdam, the Netherlands

M. Engelhardt

Universitätsklinikum Freiburg, Freiburg, Germany

M. Jenner

Southampton General Hospital, Southampton, United Kingdom

A. Corso

Division of Hematology, Hospital of Legnano, Legnano, Italy

J. Dürig

University Hospital Essen, Essen, Germany

M. Pavic

Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, Canada

M. Salomo

Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

E. Casal

Bristol Myers Squibb, Princeton, United States

R. Jiang

Bristol Myers Squibb, Princeton, United States

T. Nguyen

Bristol Myers Squibb, Princeton, United States

T. Peluso

Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

P. Richardson

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States